Phase I Study of Dose Escalation Using Image-guided Radiotherapy to Deliver a Stereotactic Radiosurgical Boost After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer

To study the safety and feasibility of stereotactic radiation dose escalation following neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating the acute and late toxicity of treatment.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Capecitabine (Xeloda)
  • drug : Carboplatin
  • drug : 5-Fluorouracil (5-FU)
  • drug : [18-F] Fluorodeoxyglucose (FDG)

Phase: Phase 1


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus by pathologist. - Endoscopic ultrasound or CT evidence of tumor penetration through the esophageal wall or involvement of regional lymph nodes, without evidence of distant metastasis - No prior chest radiation therapy - No prior chemotherapy for esophageal cancer - Age greater than 18 years - No infections requiring antibiotic treatment - Able to care for self - Patients must have acceptable liver, kidney and bone marrow function. - The effects of the chemotherapy drugs on the developing human fetus are unknown. Women of child-bearing potential and men must agree to use adequate contraception.

External Links

Explore related trials

Contact information

Primary Contact:

Laurie Ann Columbo 6507360792

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: